Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orthofix Medical (OFIX) Cash from Financing Activities (2016 - 2025)

Orthofix Medical (OFIX) has disclosed Cash from Financing Activities for 16 consecutive years, with $2.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities fell 92.45% year-over-year to $2.4 million, compared with a TTM value of -$786000.0 through Dec 2025, down 101.55%, and an annual FY2025 reading of -$786000.0, down 101.55% over the prior year.
  • Cash from Financing Activities was $2.4 million for Q4 2025 at Orthofix Medical, up from -$5.2 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $31.5 million in Q4 2024 and bottomed at -$7.6 million in Q2 2021.
  • Average Cash from Financing Activities over 5 years is $5.6 million, with a median of $1.3 million recorded in 2021.
  • The sharpest move saw Cash from Financing Activities plummeted 301.17% in 2022, then soared 7342.46% in 2023.
  • Year by year, Cash from Financing Activities stood at $2.1 million in 2021, then dropped by 27.0% to $1.5 million in 2022, then soared by 1587.58% to $25.3 million in 2023, then increased by 24.55% to $31.5 million in 2024, then plummeted by 92.45% to $2.4 million in 2025.
  • Business Quant data shows Cash from Financing Activities for OFIX at $2.4 million in Q4 2025, -$5.2 million in Q3 2025, and $2.6 million in Q2 2025.